|MDACC Study No:||2013-0433 (clinicaltrials.gov NCT No: NCT01880437)|
|Title:||A Phase IB/II Study to Evaluate the Safety and Efficacy of Vismodegib in Relapsed/Refractory Acute Myelogenous Leukemia (AML) and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS)|
|Principal Investigator:||Jorge Cortes|
|Study Description:||The goal of this clinical research study is to learn if vismodegib when given |
with and /or without Cytostar (cytarabine) can help to control relapsed or
refractory AML or MDS. The safety of this drug will also be studied.